Futura Medical PLC Appointment of Roy Davis as Non-Executive Director (9948Y)
09 Gennaio 2024 - 8:00AM
UK Regulatory
TIDMFUM
RNS Number : 9948Y
Futura Medical PLC
09 January 2024
09 January 2024
Futura Medical plc
Appointment of Roy Davis as Non-Executive Director
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the
pharmaceutical company developing innovative sexual health
products, today announces the appointment of Roy Davis as a
Non-Executive Director with immediate effect.
Roy brings a wealth of commercial experience in medical devices
companies and has a proven track record of successfully scaling
companies and delivering substantial value for shareholders. He has
held leadership positions at a number of publicly quoted med tech
companies, including CEO of Optos plc, a leading retinal imaging
device manufacturer, from 2008 to 2016 until its sale to Nikon for
GBP259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus
Group plc, a leader in minimally invasive surgery and
visualisation, until its acquisition by Olympus Corporation in 2008
for $1.9 billion.
He is currently Non-Executive Chair at LungLife AI plc, Foster
and Freeman (the trading name of the Galton group of companies) and
Rair Health Ltd and was until recently, Non-Executive Chair at
Medica Group plc until its acquisition by IK Partners for GBP269
million earlier this year. On 7 December it was announced that Roy
will become a Non-Executive Director and Chair Designate of
Inspiration Healthcare Group plc with effect from 25 January
2024.
Jeff Needham, Chairman of Futura Medical said : "Roy brings with
him significant commercial expertise and a proven track record of
creating substantial shareholder value. His appointment will add to
the depth and breadth of experience of the Futura Board as we
continue to monetise our key asset, Eroxon, move towards
profitability, and deliver on our strategy."
Roy Davis, said : "I am delighted to be joining the Board of
Futura. The Company is providing novel solutions in the sexual
health sector and has exciting opportunities ahead of it. I look
forward to working with the Board and Executive Team to help
execute the strategy and deliver shareholder value."
In accordance with Schedule 2 (g) of the AIM Rules for
Companies, Gordon Roy Davis (aged 67 years) holds/has held the
following directorships/partnerships in the last five years:
Current directorships/partnerships Previous directorships/partnerships (last
five years)
LungLifeAI, Inc Medica Group plc
Rair Health Limited Edinburgh Molecular Imaging Limited
Galton Bidco Limited
Galton Midco Limited
Galton Topco Limited
Galton Tradeco Limited
In addition to the above, Roy Davis was a director of C-Quential
Limited until his resignation on 28 February 2001. The company
entered into a creditors voluntary liquidation on 11 February 2002
and was subsequently dissolved on 18 August 2007.
Roy Davis currently holds no ordinary shares in the Company.
There are no further disclosures to be made under Schedule 2(g)
of the AIM Rules for Companies.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Ben Cryer/Nikhil Varghese
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative sexual health products based
on its proprietary, transdermal DermaSys(R) technology. Each
DermaSys(R) formulation is separately patented and specifically
tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and
patient convenience. The products are developed for the
prescription and consumer healthcare markets as appropriate.
Development and commercialisation strategies are designed to
maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction (ED) through a unique
evaporative mode of action and is sold in Europe and the UK under
the brand name Eroxon(R). Futura has conducted two Phase 3 studies
using MED3000 in ED; the FM57 study which enabled Futura to be
granted a CE Mark in 2021 and FM71 which enabled Futura to be
granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED
with a rapid speed of onset and a favourable benefit versus risk
profile ideally suited for an 'Over the Counter'
classification.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUPUBPGUPCGAR
(END) Dow Jones Newswires
January 09, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Apr 2023 a Apr 2024
